Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sandoz Completes Deal For Mycamine

Acquisition Of Antifungal Brand From Astellas Was Announced In Early 2023

Aug 29 2023

• By David Wallace

Company sign reading Sandoz A Novartis Division — Sandoz has completed its deal for rights to Mycamine • Source: Shutterstock

Related Content

Sandoz Strikes $500m Deal For GSK Cephalosporins

Feb 11 2021

Who’s Hired? Firms Ring In 2023 With Fresh Faces

Jan 13 2023

Sandoz Pushes Back On AMR And ‘Dysfunctional’ Antibiotics Market

Nov 23 2022

Sandoz To Pump Another €50m Into Kundl Antibiotics Site

Nov 07 2022

Sandoz Sets Date For Spinoff

Aug 21 2023

Related Companies

Sandoz AG

Additional Topics

Deals Strategy Infectious Diseases BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.